STAG2 and metastatic neoplasm: Within the cohort of patients with metastatic disease, 21/30 (70.0%) had retained STAG2 expression, 6/30 (20.0%) had STAG2 loss of expression, and 3/30 (10.0%) had indeterminate staining.